RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough lymphoma: targeted drug shows promise
Disease control CompletedThis phase 2 trial tested a drug called zilovertamab vedotin (MK-2140) in 140 people with diffuse large B-cell lymphoma that had returned or stopped responding to at least two prior treatments. The goal was to see how many patients had their tumors shrink or disappear. The study …
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New combo offers hope for aggressive lymphoma in diverse patients
Disease control CompletedThis study tracked 102 US adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who were treated with a combination of tafasitamab and lenalidomide. The goal was to see how safe and effective this treatment is, especially for racial and ethnic …
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental cocktail aims to tackle tough lymphoma
Disease control CompletedThis early-phase trial tested an experimental drug called OPB-111077 combined with two standard chemotherapy drugs (bendamustine and rituximab) in 36 people whose diffuse large B-cell lymphoma had come back or stopped responding to treatment. The main goal was to check the safety…
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New pill shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called XNW5004 in 120 people with advanced tumors or lymphoma that had come back or stopped responding to standard treatments. The goal was to check the drug's safety, find the right dose, and see if it helps shrink tumors. The drug is taken as a tabl…
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC